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ABSTRACT
MDM2 is an important negative regulator of p53 tumor suppressor. In this study, 
we sought to investigate the preclinical activity of the MDM2 antagonist, Nutlin-
3a, in Philadelphia positive (Ph+) and negative (Ph-) leukemic cell line models, and 
primary B-acute lymphoblastic leukemia (ALL) patient samples. We demonstrated 
that Nutlin-3a treatment reduced viability and induced p53-mediated apoptosis in 
ALL cells with wild-type p53 protein, in a time and dose-dependent manner, resulting 
in the increased expression of pro-apoptotic proteins and key regulators of cell cycle 
arrest. The dose-dependent reduction in cell viability was confirmed in primary blast 
cells from B-ALL patients, including Ph+ ALL resistant patients carrying the T315I BCR-
ABL1 mutation. Our findings provide a strong rational for further clinical investigation 
of Nutlin-3a in Ph+ and Ph- ALL.
INTRODUCTION
Acute lymphoblastic leukemia (ALL) is a malignant 
tumor of hematopoietic precursors committed to the B- 
or T-cell lineage. ALL is the most common childhood 
hematopoietic tumor; it is less common in adult people 
and generally carries a worse prognosis. The most frequent 
genetic abnormality associated with adult ALL patients 
is the t(9:22) translocation, also called Philadelphia 
chromosome (Ph) translocation [1, 2]. Despite recent 
advances in the treatment of adult and, especially, of 
childhood ALL, several disease subtypes still have a poor 
outcome and relapse due to the failure of current therapies 
caused by drug resistance or toxicity events [3, 4]. 
Therefore, novel targeted therapies are needed to improve 
the outcome of ALL patients.
P53 is a tumor suppressor protein with a key role in 
the maintenance of genetic stability and in prevention of 
cancer development [5]. In unperturbed cells the activity 
of p53 is finely regulated by MDM2 (murine double 
minute 2). This protein binds the N-terminal domain of 
p53 and inhibits its transcriptional activity. In addition, 
MDM2 has an E3 ubiquitin ligase activity that targets 
p53 to proteasomal degradation [5-7]. ARF, an alternate 
reading frame protein encoded by the tumor suppressor 
gene CDKN2A, participates to the regulation of the 
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p53 pathway by interacting with MDM2. ARF binds to 
MDM2 and prevents the ubiquitination of p53 (Figure 1), 
thereby stabilizing it [8]. Disruption of the p53 pathway 
is strongly associated with tumorigenesis. The TP53 gene 
is inactivated in 50% of human tumors by deletion or 
mutations that impair its DNA binding and transactivation 
activity [9, 10].
Different studies revealed that TP53 mutations were 
rather infrequent in ALL, but they analyzed a small cohort 
of patients and mainly childhood or relapsed cases [11-
13]. Recently, Stengel et al. demonstrated a TP53 mutation 
incidence of 15.7% in a large cohort of B- and T-ALL 
patients [14]. Moreover, most cases of ALL expressed 
wild-type TP53 but the protein does not function properly 
due to overexpression of MDM2 [15] and to deletion of 
CDKN2A gene [16, 17].
Previous studies, by Vassilev and colleagues, 
identified the first potent and selective small-molecule 
MDM2 antagonists, the Nutlins [18]. These cis-
imidazoline compounds compete with MDM2 for p53 
binding, thus preventing the formation of the p53-MDM2 
complex and the negative regulation of p53 (Figure 1) 
[19]. Nutlins have been shown to inhibit the p53-MDM2 
interaction in different cell types with a high specificity, 
leading to p53 stabilization and activation of p53 pathway, 
resulting in apoptosis or quiescence [18, 19]. Moreover, 
as a consequence of nutlin treatment, p53 may prevent 
cellular senescence, inhibiting mTOR pathway [20, 21].
It has been previously demonstrated that Nutlin-3a 
induces apoptosis in pediatric ALL with wild-type TP53 
and over-expression of MDM2 [22], and that inhibition of 
PI3K/AKT pathway synergized the ability of Nutlin-3a to 
induce apoptosis in a set of ALL cell lines [23]. Kaindl 
U. et al. also reported that co-exposure of Nutlin-3a 
and chemotherapeutic drugs reduced cell viability and 
potentiated apoptosis in childhood ALL cell lines with 
ETV6/RUNX1 fusion gene [24]. However, Nutlin-3a 
effects are still not completely elucidated in adult B-ALL. 
Thus, in the present study we investigated the therapeutic 
potential of p53 activation by Nutlin-3a in Ph+ and Ph- 
ALL cell lines and primary cells from adult B-ALL.
RESULTS
MDM2 inhibition reduces viability of Ph+ and 
Ph- leukemia cell lines and primary ALL cells
In order to investigate the effects of Nutlin-3a on 
ALL cells, we firstly analyzed cell viability of Ph+ and 
Ph- leukemic cell lines treated with increasing drug 
concentrations at different time points. The active Nutlin-
3a enantiomer significantly reduced cell viability in BV-
173 Ph+ cells (Figure 2A) in dose dependent manner 
(p<0.05 and p<0.01 at 2 μM and 5 μM, respectively) and 
in NALM-6 Ph- cells (Figure 2B) in a dose- and time-
dependent manner (p<0.01 at 5 μM) at 24 and 48 hours 
after treatment.
Numerous preclinical and clinical studies reported 
that the activation of p53 signaling, mediated by small 
molecule MDM2 inhibitors such as Nutlins, was dependent 
on the wild-type status of p53 [19, 25]. Therefore, we 
tested leukemic cell lines with wild-type, mutated or 
null p53 for sensitivity to Nutlin-3a treatment. Nutlin-3a 
efficiently inhibited the growth of Ph+ and Ph- ALL cells 
Figure 1: Schematic model for p53 activation by Nutlin-3a. The CDKN2A locus encodes ARF protein that binds MDM2. This 
interaction antagonizes the ubiquitin ligase activity of MDM2, stabilizes p53 and triggers p53 signaling. CDKN2A deletion eliminates the 
tumor surveillance mechanism based on ARF-MDM2 interaction. Nutlin-3a binds MDM2 with consequently activation of p53 pathway.
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with wild-type p53 (Figure 2C and 2D, respectively). 
In contrast, no significant changes in cell viability were 
observed in p53-null chronic myeloid leukemia (CML) 
cell line K562 (Figure 2C) and in Ph- p53-mutated ALL 
cell line REH (Figure 2D) after incubation with MDM2 
inhibitor.
We then analyzed the effect of Nutlin-3a treatment 
on the viability of primary Ph+ and Ph- ALL cells carrying 
wild-type p53, by incubating cells with 5 μM Nutlin-3a 
for 24 hours. Nutlin-3a induced a significant reduction of 
viability in 5 Ph+ and 3 Ph- ALL primary cells compared 
to their untreated counterpart (p<0.05) (Figure 2E). 
Notably, the dose-dependent reduction in cell viability 
was confirmed in primary blast cells from two Ph+ 
ALL patients with the T315I BCR-ABL1 kinase domain 
mutation, which is responsible for resistance to currently 
available TKIs (Figure 2F).
MDM2 inhibitor activates p53 pathway in ALL 
cells with wild-type p53
To investigate the effect of MDM2 inhibitor on the p53 
pathway, we analyzed the expression of p53 and its target 
genes in ALL cell lines. As expected, western blot analysis 
revealed an increased p53 protein level in the p53 wild-
type cell lines BV-173, SUP-B15, NALM-6 and NALM-
19 cells compared to the untreated control (Figure 3A). In 
addition, the activation of the p53 pathway was demonstrated 
Figure 2: Cell viability reduction in ALL cell lines after Nutlin-3a treatment. A. BV-173 and B. NALM-6 viability was 
evaluated by MTS test after treatment with increasing concentrations of Nutlin-3a (0.5 μM, 1 μM, 2 μM, 5 μM) at 24 and 48 hours. Results 
are expressed as percent viability relative to DMSO-treated controls. The bar-graphs represent mean with S.D. from three independent 
experiments. Viability of C. Ph+ (BV-173, SUP-B15 and K562) and D. Ph- (REH, NALM-6 and NALM-19) leukemic cell lines was 
evaluated by MTS test after treatment with increasing concentrations of Nutlin-3a treatment (0.5 μM, 1 μM, 2 μM, 5 μM) at 24 hours. 
E. Trypan blue count was performed in primary cells, isolated from 9 Ph+ (UPN 1-9) and 5 Ph- (UPN 10-14) ALL patients after 24 hours of 
Nutlin-3a treatment at 5 μM concentration (or DMSO-control). F. Viability of mononuclear cells isolated from 2 ALL patients (UPN 15-16) 
harboring T315I mutation was evaluated by MTS test after 24 hours of Nutlin-3a treatment at 1 μM and 5 μM concentrations. Results are 
expressed as percent viability relative to DMSO-treated controls. The bar-graphs represent mean with S.D. Statistically significant analyses 
are indicated by asterisks: *p<0.05, **p<0.01.
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by increased expression of p53 downstream target, p21, 
and activation of the cleaved caspase-7 apoptotic marker. 
Furthermore, Nutlin-3a exposure increased p53 protein levels 
in p53-mutated REH cells, but the protein was functionally 
inactivated; thus, no activation of p53 pathway was observed 
(Figure 3A). Caspase 3/7 signaling was also detected by 
cytometric analysis showing a significant increase of caspase 
3/7 activation in BV-173, SUP-B15, NALM-6 and NALM-
19 cells (p<0.05) (Figure 3B) after treatment with 5 μM of 
Nutlin-3a but not in REH cells.
Inhibition of MDM2 induces apoptosis in Ph+ 
and Ph- leukemia cell lines
To better characterize the reduction of cell viability 
induced by Nutlin-3a treatment in ALL cells, we 
determined the percentage of apoptotic cells after MDM2 
inhibitor treatment in ALL cell lines. Our data showed that 
Nutlin-3a significantly induced a dose- and time-dependent 
apoptosis in BV-173 (from 6% to 53% at 24 hours and 
from 8% to 82% at 48 hours) (Figure 4A), SUP-B15 (from 
2% to 12% at 24 hours and from 5% to 20% at 48 hours) 
(Figure 4B) and NALM-6 (from 3% to 20% at 24 hours 
and from 10% to 48% at 48 hours) (Figure 4C) ALL cell 
lines with wild-type p53, using 1 μM, 2 μM and 5 μM 
of Nutlin-3a. By contrast, REH cells, that harbored p53 
mutation, did not show significant differences in viability 
after Nutlin-3a treatment (Figure 4D).
Nutlin-3a enhances cell viability reduction in Ph+ 
ALL cell lines in combination with TKIs
We exposed BV-173 and SUP-B15 cell lines to 
increased concentrations of Nutlin-3a in combination 
with the TKIs Imatinib, Nilotinib or Dasatinib. The 
combination of Nutlin-3a and Imatinib, Nilotinib or 
Dasatinib significantly reduced viability of BV-173 cells 
in a dose dependent manner after 24 hours of treatment, 
compared with single TKI treatment (Figure 5A, 5B, 5C). 
In SUP-B15 the co-exposure of Nutlin-3a and TKIs is less 
effective (Figure 5D, 5E, 5F); in fact, only the combination 
of Nutlin-3a and Imatinib caused a significant reduction 
of viability, as shown in Figure 5D. Moreover, since 
SUP-B15 cell line was resistant to Nilotinib treatment, the 
combination of Nutlin-3a and Nilotinib (Figure 5E) had 
the same effect of Nutlin-3a alone on cell viability.
Figure 3: Activation of p53-downstream pathway by MDM2 inhibition in ALL cells with wild-type p53. A. Western blot 
analysis of p53, caspase-7, p21 and actin was performed in BV-173, SUP-B15, NALM-6, NALM-19 and REH cell lines after treatment 
with increasing concentrations of Nutlin-3a (1 μM, 2 μM, 5 μM) or DMSO control (0.1%) at 24 hours. B. Caspase 3/7 activity assay was 
performed in BV-173, SUP-B15, NALM-6, NALM-19 and REH cell lines after treatment with increasing concentrations of Nutlin-3a 
(1 μM, 2 μM, 5 μM) or DMSO control (0.1%) at 24 hours. Statistically significant analyses are indicated by asterisks: *p<0.05.
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Gene expression signature is associated with 
response to MDM2 inhibitor
To elucidate the molecular consequences of p53 
activation upon Nutlin-3a exposure in ALL cells and to 
identify novel potential biomarkers of clinical activity, we 
performed gene expression profile analysis of the Nutlin-3a 
sensitive cell lines BV-173 and SUP-B15 after 24 hours of 
drug exposure and compared them with DMSO-treated cells 
(DMSO 0.1%). A total of 621 genes (48% down-regulated 
versus 52% up-regulated) were differentially expressed 
(p<0.05). They included genes involved in cell cycle and 
apoptosis control (e.g. Histone H1, TOP2, GAS41, H2AFZ), 
in the down-regulation of Hedgehog signaling (e.g. BMI-
1, BMP7, CDKN1C, POU3F1, CTNNB1, PTCH2) and 
stemness genes, as well as in the down-regulation of genes 
with a role in the inhibition of INK4/ARF. Both GAS41 
(growth-arrest specific 1 gene) and BMI1 (a polycomb 
ring-finger oncogene) are repressors of INK4/ARF and p21 
genes and their aberrant expression contributes to stemness 
maintenance in malignant cells [26, 27]. Moreover, the 
reduction of BMI-1 protein levels was associated with 
apoptosis in tumor cells and increased susceptibility to 
cytotoxic agents and radiation therapy [28]. BMI-1 and 
GAS41 were down-regulated after in vitro treatment with 
Nutlin-3a (fold-change: -1.10 and -1.35, respectively; 
p-value 0.03 and 0.01, respectively) (Table 1). Since BMI-
1 has a crucial role in the control of apoptosis, we validated 
microarray data by Western blot analysis. BMI-1 protein 
expression decreased in BV-173 cells after Nutlin-3a 
treatment (Figure 6A), while they remained constant in the 
others Ph+ and Ph- cell lines (Figure 6A).
We further investigated BMI-1 transcript expression 
in primary blast cells from Ph+ and Ph- ALL patients 
after in vitro treatment with Nutlin-3a observing a trend 
of reduction in Ph+ ALL cells if compared with their 
untreated counterparts (Figure 6B); instead, Ph- ALL 
samples showed a different expression of BMI-1 after 
treatment (Figure 6C).
DISCUSSION
P53 pathway is negatively regulated by the interaction 
between p53 and MDM2 proteins [39]. MDM2 is in turn 
regulated by ARF tumor suppressor; this binding prevents 
p53 ubiquitination and activate p53 response [40].
Figure 4: Induction of apoptosis in ALL cells after Nutlin-3a treatment. Apoptosis induction was evaluated in A. BV-173, 
B. SUP-B15, C. NALM-6 and D. REH cell lines by Annexin V test after 24 and 48 hours of Nutlin-3a treatment at increasing concentrations 
(1 μM, 2 μM, 5 μM). Results are expressed as percent apoptosis relative to DMSO-treated controls. The bar-graphs represent mean with 
S.D. from three independent experiments. Statistically significant analyses are indicated by asterisk: *p<0.05.
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It has been recently shown that ARF deletions 
frequently occur in Ph+ ALL patients and contribute to 
resistance to targeted therapy in ALL induced by BCR-
ABL1 [16, 41]. Since MDM2-mediated p53 inhibition is 
a main inhibitory mechanism in tumors retaining wild-
type p53, targeting the MDM2-p53 interaction by small 
molecules, like Nutlin-3a, represents a novel potential 
therapeutic strategy to reactivate p53 in cancer [42].
In this study we demonstrated that Nutlin-3a induces 
growth arrest and apoptosis in Ph+ and Ph- ALL cells with 
wild-type p53, in a dose and time dependent manner. No 
significant changes in cell viability and apoptosis were 
observed in p53-null and p53-mutated cell lines after 
incubation with MDM2 inhibitor, confirming that the p53 
pathway can be preferentially activated by Nutlin-3a in 
cells with wild-type p53. Nutlin-3a treatment activated p53-
mediated apoptosis mechanisms, inducing the increased 
expression of proapoptotic proteins and key regulators of 
cell cycle arrest in ALL cell lines and primary blast cells.
Given the clinical importance of BCR-ABL1 
mutations, we tested the efficacy of Nutlin-3a in primary 
blast cells isolated from ALL patients with T315I mutation 
that confers resistance to available TKIs. We observed that 
Nutlin-3a reduced cell viability, suggesting a potential 
alternative therapy for patients resistant to TKIs treatment.
To elucidate the clinical power of this class of 
compound, we evaluated the effect of the combination 
between Nutlin-3a and the TKIs which are currently 
used in Ph+ ALL therapy. In particular, we evaluated the 
co-treatment of Nutlin-3a with Imatinib, Nilotinib and 
Dasatinib, in Ph+ cell lines. The strongest effect was found 
in BV-173 cell line in which the combination between 
Nutlin-3a and Imatinib or Nilotinib reduced cell viability 
of about 40% and 30%, respectively, in comparison with 
the effect of the single TKI treatment. A less effect of 
about 10%, even so statistically significant, was observed 
in BV-173 treated with Nutlin-3a and Dasatinib. Thus, 
Nutlin-3a can potentiate the effects of TKIs treatment. 
Furthermore, SUP-B15 is less responsive to the drugs 
combination. In fact, a significant reduction of viability 
was only observed in the co-exposure of Nutlin-3a and 
Imatinib, of about 25%.
Gene expression profile of Nutlin-3a sensitive cells 
allowed us to identify potential biomarkers of Nutlin-
3a clinical activity. In particular, we studied BMI-1 
protein involved in control of apoptosis and regulation of 
CDKN2A and p21 genes [43, 44]. BMI-1 expression is 
markedly reduced in BV-173 sensitive cells and it could 
be a biomarker of therapeutic response. We also observed, 
although in a small number of Ph+ ALL samples, a trend of 
reduction of BMI-1 transcript after in vitro treatment with 
Nutlin-3a. Thus, BMI-1 role needs to be later confirmed in 
clinical settings in a large cohort of patients.
Finally, our findings provide a strong rationale for 
further clinical investigation of Nutlin-3a in Ph+ and Ph-
 ALL. Small-molecule MDM2 antagonists, which target 
the p53-MDM2 interaction leading to p53-mediated 
apoptosis, may synergize with current TKIs-based 
therapies in Ph+ ALL patients with wild-type p53 and may 
represent a valuable strategy for TKIs resistant patients. 
Moreover, Nutlin-3a may be a novel therapeutic agent for 
Ph- ALL patients with wild-type p53.
Figure 5: Effect of MDM2 inhibitor and TKIs combination on ALL cell lines. A, B, C. BV-173 and D, E, F. SUP-B15 
viability was evaluated by MTS test after 24 hours of Nutlin-3a (Nut) treatment (0.5 μM, 1 μM, 2 μM) alone or in combination with 
(A, D) Imatinib (IM) (50 nM, 100 nM, 250 nM) or (B, E) Nilotinib (Nil) (25 nM, 50 nM, 100 nM) or (C, F) Dasatinib (Das) (10 nM, 100 
nM, 500 nM). Results are expressed as percent viability relative to DMSO-treated controls. The bar-graphs represent mean with SD from 
three independent experiments. Statistically significant analyses are indicated by asterisks: *p<0.05, **p<0.01.
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Figure 6: Gene expression signature associated with Nutlin-3a treatment. A. Western blot analysis of BMI-1 and actin was 
performed in BV-173, SUP-B15, NALM-6, NALM-19 and REH cell lines after 24 hours treatment with increasing concentrations of 
Nutlin-3a (1 μM, 2 μM, 5 μM) and with DMSO control. BMI-1 mRNA relative expression in primary cells, isolated from B. 9 Ph+ (UPN: 
1-9) and C. 3 Ph- ALL patients (UPN: 10-12), was determined by qRT-PCR assay after 24 hours of 5 μM Nutlin-3a (Nut) treatment.
Table 1: The table reported differentially expressed genes between control (DMSO) and BV-173 and SUP-B15 
sensitive cells treated with 2 μM of Nutlin-3a for 24 hours 
Gene 
Symbol
Description Function Fold 
change
p-value Ref.
BMI-1
B cell-specific Moloney murine 
leukemia virus integration site 1; 
Polycomb Repressor Complex 1
Epigenetic repression, chromatin 
remodeling, modification of 
hystones
-1,1053 0,0337587 [29, 30]
GAS41
Glioma-amplified sequence 
41; YEATS domain-containing 
protein 4
Transcriptional regulation, 
chromatin remodeling -1,34902 0,0159932 [31]
H2AFZ H2A Histone family member Z DNA damage response pathway -1,10123 0,0098745 [32]
H1FX H1 Histone family member X Nucleosome assembly -1,42939 0,0084268 [33]
SETD1A Histone H3-lysine N-methyltransferase
Regulation of chromatin structure, 
gene expression -1,12061 0,0112585 [34, 35]
TBL1XR1 Transducin (β)-like 1 X-linked receptor 1 Transcriptional regulation -1,08508 0,0311275 [36, 37]
SUPT3H Suppressor of Ty 3 homolog Transcriptional regulation 1,11364 0,0493653 [38]
Both GAS41 and BMI-1 were down-regulated after Nutlin-3a in vitro treatment (fold-change: -1.35 and -1.11, respectively; 
p=0.02 and p=0.03, respectively).
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MATERIALS AND METHODS
Patients
Bone marrow (BM) and/or peripheral blood (PB) 
samples were obtained from 11 Ph+ and 5 Ph- ALL patients, 
upon written informed consent, according to the Declaration 
of Helsinki. Primary blast cells were isolated by density 
gradient centrifugation over Lymphoprep (Nycomed UK, 
Birmingham). All patients had TP53 wild-type sequence; two 
Ph+ ALL patients harbored T315I mutation in the BCR-ABL1 
kinase domain. Patient characteristics are shown in Table 2.
Cell lines
Human Ph+ (BV-173 and SUP-B15) and Ph- (NALM-
6, NALM-19 and REH) ALL cell lines, and Ph+ CML cell 
line (K562) were obtained from DSMZ (Braunschweig, 
Germany). Ph+ cell lines, BV-173, SUP-B15 and K562, 
were cultured in RPMI 1640 medium supplemented with 
20% fetal bovine serum (FBS), 1% penicillin-streptomycin, 
and 2 mM L-glutamine (Gibco, Life technologies, Carlsbad, 
CA, USA). Ph- ALL cell lines, NALM-6, NALM-19 and 
REH, were cultured in RPMI 1640 medium supplemented 
with 10% FBS, 1% penicillin-streptomycin and 2 mM 
L-glutamine (Gibco). Cells were grown at 37°C in 5% 
CO2. All the cell lines harbored homozygous CDKN2A 
deletion. BV-173, SUP-B15, NALM-6 and NALM-19 cell 
lines lacked genetic alteration of TP53. REH cells harbored 
heterozygous substitution of C>T at position:17:7578389 at 
codon 181 (R181C) causing functional inactivation of p53 
protein; K562 cells were p53-null.
Reagents and cell treatment
The small-molecule MDM2 inhibitor, Nutlin-3a, 
was dissolved in DMSO (10 mM stock solution) and 
stored at -80°C. ALL cells were exposed to increasing 
concentration of Nutlin-3a (0.5 to 5 μM) for the indicated 
times. Control cells were treated with DMSO 0.1%. Cells 
were treated with TKIs at the following concentrations: 50 
nM, 100 nM and 250 nM Imatinib, 25 nM, 50 nM and 100 
nM Nilotinib, 10 nM, 100 nM, 500 nM Dasatinib.
RNA extraction
Total RNA was extracted using the RNA Blood Mini 
Kit (Qiagen GmbH, Hilden, Germany) from mononuclear 
Table 2: Clinical characteristics of ALL patients
UPN Gender Age Sample 
Type
Lineage BCR-ABL1 
fusion gene
TP53 
status
Karyotype
1 F 69 BM BCP + Wt 46,XX,t(9;22)(q34;q11)
2 M 46 BM BCP + Wt 46,XY,t(9;22)(q34;q11)
3 M 78 BM BCP + Wt 46,XY,t(9;22)(q34;q11)
4 M 30 BM BCP + Wt N/A
5 M 70 BM BCP + Wt 45,XY,-7,t(9;22)(q34;q11)
6 F 62 PB BCP + Wt
46,XX,t(9;22)
(q34;q11)/46,XX,del(9)
(p13p22),t(9;22)(q34;q11)/46,XX
7 M 69 PB BCP + Wt 49XY,+der(3),del(3)(p11),+4,der(5)del(5)(p11),t(9;22)(q34;q11)
8 M 64 PB BCP + Wt N/A
9 M 69 BM BCP + Wt 46, XY,t(9;22)(q34;q11)
10 F 79 PB BCP - Wt
45,XX,der(7)t(7;?)(p11;?),del(8)
(q22),add(9)(p21),-9,der(16)t(1;16)
(q31;p13)
11 F 51 BM BCP - Wt 46,XX
12 F 75 PB BCP - Wt N/A
13 F 62 BM BCP - Wt 46,XX
14 M 76 BM BCP - Wt 46,XY
15 F 65 BM BCP + N/A 46,XX,t(9;22)(q34;q11)
16 M 72 BM BCP + N/A 46,XY,t(9;22)(q34;q11)
Abbreviations: UPN, unique patient number; BCP: B cell precursor; wt: wild-type; N/A: not applicable.
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cells isolated from BM and PB samples. RNA was 
quantified using the Nanodrop Spectrophotometer and 
quality was assessed using the Nanodrop and by agarose 
gel electrophoresis.
Cell viability assay
Cell viability was measured by colorimetric 
Methanethiosulfonate (MTS) test (Promega, Inc., 
Madison, WI). Cells were cultured in 96-well plates at 
5x104 cells/100μl with different drug concentrations at 
37°C. MTS (0.33 mg/ml per well) was added to each well 
and the cells were incubated for an additional 3 hours. 
Following incubation, the optical density was read at 
490 nm wavelength. Cellular viability was calculated as 
percentage of viable cells compared with control (DMSO 
0.1%). All experiments were conducted in triplicate. 
Primary ALL cells were seeded in 6-well plates at 5x105 
cells/mL with increasing concentrations of drug for 24 
hours and incubated at 37°C. Cell viability was assessed 
by counting viable and non-viable cells by Trypan blue 
dye exclusion method. Cellular viability was calculated as 
percentage of viable cells compared with control (DMSO 
0.1%).
Western blotting
Cells were lysed in RIPA buffer (50 mM Tris-HCl 
pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% Na Deoxycholate, 
0,1% SDS, 1 mM PMSF, complete Protease Inhibitors 
Cocktail, Roche). For Western blot analysis, the NuPAGE 
Electrophoresis System was used, according to the 
manufacturer’s instructions (Life technologies). Equal 
amount of protein extract was transferred to nitrocellulose 
membranes. The membranes were blocked with 5% milk 
at room temperature for 1 hour and incubated over night 
at 4°C with primary antibodies directed towards actin 
(1:1000; Sigma Aldrich, St Louis, MO, USA, A2066), 
p53 (1:500; Cell Signaling Techonology, Inc. MA, USA, 
#2524), BMI-1 (1:1000, Cell Signaling Techonology, 
#6964), p21/WAF1/Cip1 (1:500; Millipore, Billerica, 
MA, USA, 05-345), caspase-7 (1:1000; Cell Signaling 
Techonology, #9492), followed by incubation with 
horseradish peroxidase-conjugated secondary antibodies 
at room temperature for 1 hour (1:2000 anti-mouse, 115-
035-003 or 1:2000 anti-rabbit, 111-035-003, Jackson 
ImmunoResearch Laboratories, INC, PA, USA). Protein 
bands were visualized using an ECL chemiluminescent 
detection system (Amersham, IL, USA).
Caspase 3/7 activity assay
Caspase 3/7 activity was measured with the 
CellEventTM caspase 3/7 Green Detection Reagent (Life 
technologies). On cleavage by activated caspase 3/7, 
the probe becomes fluorescent and free to bind to DNA. 
Cells were incubated with 1 μM CellEventTM caspase 3/7 
green detection reagent in complete medium for 30 min 
at 37°C in the dark. Stained cells were observed by flow 
cytometry.
Apoptosis
Flow cytometry was performed to detect apoptotic 
cells after Nutlin-3a treatment. ALL cells were seeded 
in 6-well plate at 5x105 cells/mL and treated with 
increasing concentrations of Nutlin-3a or vehicle control 
(DMSO 0.1%), for different times. After treatment, cells 
were washed twice in Annexin V binding buffer (0.1 M 
Hepes/NaOH pH 7.4, 1.4 M NaCl and 25 mM CaCl2), 
stained with Annexin V-FITC/Propidium Iodide (PI) 
(BD Biosciences, San Jose, CA, USA) and analyzed by 
FACSCalibur flow cytometry (BD Biosciences).
Microarray experiments
Gene expression profiling was performed using 
Affymetrix GeneChip Human Gene 1.0 ST platform 
(Affymetrix, Santa Clara, CA, USA). Raw data were 
normalized by using the RMA algorithm and filtered. 
Genes differentially expressed were selected by analysis 
of variance (ANOVA) (p-value threshold=0.05, Partek 
Genomics Suite). The most significantly involved process 
networks were defined by GeneGo software.
BMI-1 mRNA expression level
One μg of total RNA was used to synthesize the 
first strand cDNA using Transcriptor First strand cDNA 
Synthesis Kit (Roche). BMI-1 expression was evaluated 
by quantitative real-time PCR (qRT-PCR), performed 
on Light Cycler 480 II (Roche) with Taqman assay (Life 
technologies, Carlsbad, CA, USA) using 50 ng of cDNA 
at the following conditions: 95°C for 10 min, 40 cycles 
at 95°C for 10 sec, 60°C for 10 sec, 72°C for 15 sec. 
Each sample was analyzed in triplicate. Relative mRNA 
expression values were normalized using GAPDH as 
reference gene and calculated using the E-ΔΔCp method.
Statistical analysis
Statistical analysis was performed by ANOVA in 
cell lines viability after Nutlin-3a treatment alone or in 
combination with TKIs, and apoptosis. Student’s t-test 
was used to assess differences in primary cell viability, 
in caspase 3/7 activation and in BMI-1 expression after 
Nutlin-3a treatment. A p-value <0.05 was considered 
statistically significant.
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